Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peginterferon Lambda-1a and Daclatasvir in Naive Genotype 2/3 Chronic Hepatitis C
NCT01616524Phase 3
Key facts
- Status
- Completed
- Start
- Jul 2012
- Primary completion
- Jun 2014
- Countries
- 19
- Sponsor
- Bristol Myers Squibb
- Modality
- Cytokines & Interferons
- Conditions
- hepatitis C (HCV)
01
Overview
Phase 3, randomised, double-blind trial of peginterferon lambda-1a in hepatitis C (HCV), sponsored by Bristol Myers Squibb. Started Jul 2012; status: completed.
02
Design
- Study design
- RandomizedDouble-blind
03
Registry description
The purpose of this study is to determine if 24 weeks of treatment with Pegylated Interferon Lambda plus Ribavirin and 12 weeks of treatment with Pegylated Interferon Lambda plus Ribavirin and Daclatasvir will be safe and effective for treatment of hepatitis C compared to 24 weeks of treatment with Pegylated Interferon Alfa-2a plus Ribavirin
Beyond the preview
Go deeper on NCT01616524.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01616524.